articles+ search results

130 articles+ results

View results as:
Number of results to display per page

4. Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors

5. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

6. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

7. Enhancement of Lexatumumab-induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner

8. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin

9. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers

10. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels

11. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.

18. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells

19. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.


Books, media, physical & digital resources


Course- and topic-based guides to collections, tools, and services.